Press Release

February 26, 2019
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019

BOSTON--(BUSINESS WIRE)--Feb. 26, 2019-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on Tuesday, March 12, 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2018.

The call can be accessed by dialing (877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international), five minutes prior to the start of the call and providing the passcode 2849017. The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcast will be archived on the Company's website for 90 days following the call.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.

Source: Verastem, Inc.

Verastem Oncology:
Erin Cox
Senior Director, Investor Relations and Corporate Communications
+1 781-469-1553
ecox@verastem.com

Investors:
Joseph Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com